NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.17). The biopharmaceutical company earned $0.24 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

2 brokerages have issued 1 year price objectives for Navidea Biopharmaceuticals' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Navidea Biopharmaceuticals' share price to reach $2.50 in the next year. This suggests a possible upside of 123.2% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

Media headlines about NAVB stock have been trending somewhat negative on Thursday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Navidea Biopharmaceuticals.

Navidea Biopharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 664,900 shares, a decrease of 7.0% from the January 15th total of 715,300 shares. Based on an average daily volume of 608,700 shares, the short-interest ratio is currently 1.1 days. Approximately 6.0% of the shares of the stock are sold short. View Navidea Biopharmaceuticals' Current Options Chain.

Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Rexahn Pharmaceuticals (REXN), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX) and Gilead Sciences (GILD).

Navidea Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Allred Capital Management LLC (0.13%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

NAVB stock was bought by a variety of institutional investors in the last quarter, including Allred Capital Management LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Insider Buying and Selling for Navidea Biopharmaceuticals.

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NAVB stock can currently be purchased for approximately $1.12.

Navidea Biopharmaceuticals has a market capitalization of $20.25 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.